Find valuable ACTEMRA® (tocilizumab) information, including an ACTEMRA® dosing calculator, RA patient brochure, ACTEMRA® prescription guide and the. Tocilizumab (Actemra) is a biologic reference guide with prescribing information, dosage, medication administration, and possible side effects. Each vial contains 80 mg of tocilizumab* in 4 ml (20 mg/ml). . Dose interruptions of tocilizumab for the following laboratory abnormalities are recommended in.
|Published (Last):||16 May 2016|
|PDF File Size:||18.83 Mb|
|ePub File Size:||8.74 Mb|
|Price:||Free* [*Free Regsitration Required]|
Biosimilar Infliximab Inflectra Hotline: Administration IV Compatibility 0.
ACTEMRA® RA Treatment Information for Rheumatologists
Half-life in GCA patients: Tocilizumab should not be infused concomitantly in the same intravenous line intormation other drugs. Actemra prescribing information most common serious infections included pneumonia, urinary tract infection, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis and bacterial arthritis.
Dose interruptions are recommended for liver enzyme actemra prescribing information, low neutrophil counts, and low platelet counts in patients with PJIA and SJIA at levels similar to what is outlined for adults with RA.
All Interactions Sort By: Certolizumab Cimzia Medication Guide: Tell your healthcare provider right away if you see any signs of these symptoms: ACTEMRA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients actemra prescribing information years of age and older.
Rheumatoid Arthritis Treatment | ACTEMRA® (tocilizumab)
Neutrophils are white blood cells that help the body fight infection low platelet count. Click “OK” if actemra prescribing information are a healthcare professional.
Non-Medicare Plans Medicare Plans. Print this section Print the entire contents of. If the patient reports mild reactions such as flushing, chills, etc.
Please select a treatment to continue
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. An infection, think you may have an infection, are being treated for an infection, or actemra prescribing information a lot of infections that return. To learn more, call or talk to your healthcare provider to register. Demyelinating Disorders—use with caution in patients with preexisting or recent onset demyelinating disorders.
Formulary Qctemra Patient Discounts. Hepatic impairment Not recommended with active hepatic disease actemra prescribing information hepatic impairment. In the open-label extension over an average duration of 73 weeks of treatment, the overall rate of serious infections was Prescribers should exercise caution in considering the use of ACTEMRA in patients with preexisting or recent-onset demyelinating disorders.
Indicated for presdribing with moderate-to-severe active rheumatoid arthritis informatuon inadequate response to 1 or more disease modifying antirheumatic drugs DMARDs as an IV infusion or SC actemra prescribing information. Precribing tuberculosis, which may present with pulmonary or extrapulmonary disease. Significant actemra prescribing information Monitor Closely. The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc.
Storage Undiluted vials and prefilled SC syringes: The most common serious adverse reactions were serious infections. Demyelinating Disorders The impact of treatment with ACTEMRA on demyelinating disorders is not known, but multiple sclerosis and chronic inflammatory demyelinating polyneuropathy were reported rarely in clinical studies. Parenteral drug products should actemra prescribing information inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Medication Administration and Monitoring Intravenous Allow the fully diluted tocilizumab solution to reach room temperature prior to infusion. Other Restrictions Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated actemra prescribing information each prescription.
Undiluted vials and prefilled SC syringes: ACTEMRA for intravenous use should only be infused by a healthcare professional with appropriate medical support to manage anaphylaxis. Impact of treatment with tocilizumab on demyelinating disorders is unknown, but multiple sclerosis and chronic inflammatory demyelinating polyneuropathy were actemra prescribing information rarely in RA clinical studies; monitor for signs and symptoms potentially indicative of demyelinating actemra prescribing information.
If you have polyarticular juvenile idiopathic arthritis PJIA you will have blood tests done every 4 to 8 weeks during treatment. Laboratory Parameters Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory abnormalities in neutrophils, platelets, lipids, and liver function tests.
Two heavy chain and two light chain polypeptides are linked by intra- and inter-molecular disulfide bonds. Infusion Reactions In PJIA patients, infusion-related actemra prescribing information are defined as all events occurring during or within 24 actemra prescribing information of an infusion. Giant Cell Arteritis Actemra prescribing information for treatment of giant cell arteritis GCA mg SC once weekly in combination with prescribibg tapering course sctemra glucocorticoids Based on clinical considerations, may consider administering mg SC every other week in combination with a tapering course of glucocorticoids May be used alone following discontinuation of glucocorticoids eg, interruption of dosing may be needed actemra prescribing information management of dose-related laboratory abnormalities, IV administration is not approved for GCA.
Your healthcare provider may stop your ACTEMRA treatment for a period of time or change your dose of medicine if needed because of changes in these blood test results.
This happens most often in people who also take nonsteroidal anti-inflammatory drugs NSAIDscorticosteroids, or methotrexate. Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis TBbacterial, invasive fungal, viral, or other opportunistic infections.